Clinical trial
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00390299 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00390299 |
|---|---|
| Title | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM) |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma, Recurrent Glioblastoma |
| Intervention type | Biological, Other, Procedure |
| Interventions | Carcinoembryonic Antigen-Expressing Measles Virus, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery |
| Enrollment | 23 |
| Start date | Oct 23, 2006 |
| Primary completion | Nov 29, 2018 |
| Completion | Nov 30, 2019 |
| First posted | Oct 19, 2006 |
| Last update posted | Jan 2, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: